Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. - Wikidata - wikimedia - TriplyDB

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

http://www.wikidata.org/entity/Q37952231

about

Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.Clinical application of multidisciplinary teams in tumor therapy.Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.The importance of a multidisciplinary approach to hepatocellular carcinoma.Treatment of hepatocellular carcinoma: present and future.Multidisciplinary approach for HCC patients: hepatology for the oncologists.Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.Refining sorafenib therapy: lessons from clinical practice.Sorafenib: 10 years after the first pivotal trial.Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.Dietary supplementation in cancer patients: a personal view of current status and future perspectives.Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis.European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?

P2860

Q30486078-4C09C369-A2F8-4AA5-94B9-7BA39C859D77 Q33649984-141B52CF-E7E9-4B3A-8AD4-075A17AC84AA Q35399206-46D3B708-0B46-4FD3-AE43-F15FBB201575 Q36309974-5A08C97A-CAAB-4ED5-A0BF-AAD4E0F5CBCE Q37720697-0FF0802E-EC56-46E7-B209-AC697469FE8C Q38096477-60DCECF2-EA6C-429C-9658-38223254E773 Q38110202-ED70D581-FCDE-464C-872E-C336DDF76452 Q38162294-7BC1E79D-60AE-41B5-BAC1-BAE79A28A6F9 Q38213650-F3A70378-42F2-4C8E-9840-2ADE0596B381 Q38264146-1319C987-7667-43C3-86EB-C80AF17168CC Q38544841-4A48C462-E523-49FB-B7B0-C3848F50AD2A Q39374939-22B2CB4B-1478-4773-BC55-F0E61717DB16 Q44019395-D472D5EB-ABE0-41C9-B4FF-85D39EAE5CD4 Q46283204-F09F8B1E-B0EE-4075-A559-796D4104F540 Q48760305-35DDB765-5167-46F4-9739-297641D320C0

P2860

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

http://www.wikidata.org/entity/Q37952231

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

@en

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

@nl

type

label

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

@en

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

@nl

prefLabel

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

@en

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

@nl

P1433

Q37952231-02BB2869-F522-46B8-BC8C-79A5F10982A7

P1476

Q37952231-5AE4B917-4E43-4694-8F43-1526C099BB0B

P2093

Q37952231-186BC214-F7A4-4AC9-9041-355BDBCF50C7

Q37952231-527CAC17-E6D9-4544-B6CA-7CACB33A8649

Q37952231-546B7994-22BB-44E0-A6D8-729E43EECB09

Q37952231-71ADB31D-ED35-4E30-BB5E-753E2819BB5F

Q37952231-7360BD85-482C-4FB2-A686-92E2C33D45E8

Q37952231-B85092FB-BA09-4DA6-A6F3-DF909EE73C4F

Q37952231-CF519553-68F7-4BA3-AB04-CAC64D91BE2A

Q37952231-EB3C2119-882F-476A-AA6E-6D539FE22583

P2860

Q37952231-17804AAF-C509-419D-A80E-5DBD5216046F

Q37952231-1BED89B9-E871-4C51-AB8A-687E2A2A4B9A

Q37952231-22DAA4F3-EC51-4986-8235-BDADDE7586AE

Q37952231-3D373306-0AD9-48CC-8CAE-135A793308B4

Q37952231-45216E3E-4340-41AB-B354-2A87852030CD

Q37952231-4C9B8638-F80D-4B7E-8FF2-BEF7E0DFCF98

Q37952231-5189F1FB-BB27-4823-9870-7F907BE7F249

Q37952231-5AECB117-ECCA-4B1C-856A-2135097B6DF4

Q37952231-66DC1125-3000-4BAA-B51B-873C864D42EC

Q37952231-70D74A1B-400A-4E3A-9BDD-94B591597AB4

P304

Q37952231-A66D7A9B-3870-4A28-942D-32801FF32459

P31

Q37952231-6F6F4B34-492C-40C6-BCA7-A8F7C45BE5E8

P356

Q37952231-76B7C75F-79B8-4F95-AD90-70F873CA49CF

P433

Q37952231-1837198C-8014-4C1E-A34C-989CD8F3205E

P478

Q37952231-DA0BF85A-B828-4D5C-892E-1D2D1C065898

P577

Q37952231-BC26195B-7457-4364-8144-86870C025BEA

P5875

Q37952231-1981BE46-CDCC-4DF5-9999-640B7B0CD881

P698

Q37952231-E154656B-AADD-4FA1-A632-01A7406D0701

P921

Q37952231-8FA41777-3FF0-40C0-9A5D-FC4B33509DB4

P356

P1433

Expert Review of Anticancer Therapy

P1476

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

@en

P2093

Chiara Genco

http://www.w3.org/2001/XMLSchema#string

Emanuela Rolle

http://www.w3.org/2001/XMLSchema#string

Francesca Spada

http://www.w3.org/2001/XMLSchema#string

Giuseppe Cabibbo

http://www.w3.org/2001/XMLSchema#string

HCC Working Group

http://www.w3.org/2001/XMLSchema#string

Massimo De Giorgio

http://www.w3.org/2001/XMLSchema#string

Rodolfo Sacco

http://www.w3.org/2001/XMLSchema#string

Tiziana Pressiani

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma

Management of hepatocellular carcinoma

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Prognosis of hepatocellular carcinoma: the BCLC staging classification

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.

P304

1807-1816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.11.139

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51767399

http://www.w3.org/2001/XMLSchema#string

P698

22049974

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis